Research has been conducted on the use of lu-psma therapy in treating prostate cancer, with studies examining its efficacy and safety in various patient populations. The therapy's role in diagnosing and treating prostate cancer is being explored, including its potential in metastatic castration-resistant cases. Different forms of psma-targeted therapy, such as lutetium-177 and actinium-225, are being investigated in various reviews and analyses.